The soft tissue sarcoma market comprises therapeutic treatments and procedures for soft tissue sarcoma tumors. Soft tissue sarcomas are rare tumors that develop in muscles, fat, blood vessels, tendons and other connective tissues throughout the body. While soft tissue sarcomas accounts for less than 1% of all adult cancers, the incidence rate has been steadily increasing in recent years.
The Soft Tissue Sarcoma Market is estimated to be valued at US$ 315 Mn in 2024 and is expected to exhibit a CAGR of 4.2% over the forecast period 2024-2031.
Wide availability of advanced treatment options and rapid diagnosis are major factors driving the market. While surgical resection remains the primary treatment for local soft tissue sarcomas, targeted drug therapies and radiation are commonly used as adjuvant or neoadjuvant treatments.
Key Takeaways
Key players operating in the soft tissue sarcoma market are Pfizer, Eli Lilly, Johnson & Johnson, GSK (GlaxoSmithKline), and Roche. These leading players account for a major share of the market currently and are focusing on expanding their product portfolios through acquisitions and partnerships.
Some of the key opportunities in the market include development of new drug targets, personalized treatments based on tumor genetics, and combination therapies. Several innovative drugs are in pipeline that can potentially widen treatment options.
Globally, the soft tissue sarcoma market is witnessing expansion in Asia Pacific and Latin America supported by growing patient awareness, healthcare spending, and demand for advanced cancer care. Major players are focusings on partnerships with local providers to strengthen presence and cater to unmet needs in emerging markets.
Market Drivers
One of the key driver for the soft tissue sarcoma market is widening target patient base. Globally increasing incidence rates of soft tissue sarcomas owing to changing lifestyle factors, better diagnosis and longer life expectancy is driving the need for efficient treatment options. According to estimates, over 13,000 new cases of soft tissue sarcoma are diagnosed in the US annually.
Market Restraints
High cost of advanced targeted therapies is a major challenge restricting wider adoption, especially in price-sensitive developing regions. Moreover, lack of comprehensive clinical data for several new treatments and resistance to existing drugs also restricts market potential to a certain extent.
Segment Analysis
The Soft Tissue Sarcoma Market is dominated by the Gastrointestinal Stromal Tumor (GIST) sub-segment. GIST accounts for approximately 20% of all soft tissue sarcomas. Rise in incidence rates of GIST worldwide along with availability of effective targeted drug therapies like imatinib/gleevec have contributed to the growth of this sub-segment. Advantages such as fewer side effects, better tolerance and improved outcomes compared to traditional chemotherapy have boosted the uptake of targeted therapies for GIST treatment. Other prominent sub-segments include Adipocytic Sarcoma, Fibrosarcoma and Synovial Sarcoma.
Global Analysis
North America represents the largest regional market, driven by rising public awareness about soft tissue sarcomas, increasing research funding for treatment development and presence of advanced healthcare facilities. The region accounts for approximately 40% revenue share. Asia Pacific region is expected to witness highest growth during the forecast period owing to rapid economic development, growing healthcare expenditure, increasing patient population and improvingaccess to diagnosis and treatment. China, Japan and India are expected to be the major revenue contributers to the Asia Pacific regional market. Initiatives undertaken by governments in the region to modernize healthcare infrastructure will aid market expansion.
Get more insights on this topic: https://www.pressreleasebulletin.com/the-growing-soft-tissue-sarcoma-market-is-in-trends-by-increasing-prevalence-of-cancer/
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)
What Are The Key Data Covered In This Soft Tissue Sarcoma Market Report?
:- Market CAGR throughout the predicted period
:- Comprehensive information on the aspects that will drive the Soft Tissue Sarcoma's growth between 2024 and 2031.
:- Accurate calculation of the size of the Soft Tissue Sarcoma and its contribution to the market, with emphasis on the parent market
:- Realistic forecasts of future trends and changes in consumer behaviour
:- Soft Tissue Sarcoma Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa
:- A complete examination of the market's competitive landscape, as well as extensive information on vendors
:- Detailed examination of the factors that will impede the expansion of Soft Tissue Sarcoma vendors
FAQ’s
Q.1 What are the main factors influencing the Soft Tissue Sarcoma?
Q.2 Which companies are the major sources in this industry?
Q.3 What are the market’s opportunities, risks, and general structure?
Q.4 Which of the top Soft Tissue Sarcoma companies compare in terms of sales, revenue, and prices?
Q.5 Which businesses serve as the Soft Tissue Sarcoma’s distributors, traders, and dealers?
Q.6 How are market types and applications and deals, revenue, and value explored?
Q.7 What does a business area’s assessment of agreements, income, and value implicate?
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it